

Performance in Delivering Clinical Trial Research Q2 2017 - 2018  
Time to Target (Commercial Contracts)  
Studies that have Closed to Recruitment in the Previous 12 months

Research Ethics Number	IRAS number	Name of Trial	Agreed Target of patients	Target Range Agreed? (min/max)	Target Date Agreed?	Total Recruited by Agreed Target Date	Total Number of Study Participant	Recruitment end date	Trial Status	Target met	Comments
13/lo/1758	136392	APECS Prodromal: A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal A	10	Yes (10/10)	Yes (31/10/2014)	10	10	31/10/2016	Recruitment Finished	Yes	Study closed. Recruitment target met
15/SS/0032	165287	An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease	1	No	Yes (09/12/2015)	4	4	09/02/2017	Recruitment Finished	Yes	Study closed. Recruitment target met
15/SC/0432	181387	A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatment-resistant Depression TRANSFORM (ESKETINTRD3005)	2	No	Yes (24/05/2017)	0	0	15/05/2017	Withdrawn By Sponsor	No	Sponsor terminated recruitment early due to global target being met
15/SC/0434	181955	An open-label, long-term, safety and efficacy study of intranasal Esketamine in Treatment-resistant Depression in Adults SUSTAIN-2 (ESKETINTRD3004)	4	No	Yes (31/07/2017)	4	4	27/03/2017	Recruitment Finished	Yes	Study closed. Recruitment target met
16/SC/0363	205067	RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE (STEADFAST)	3	No	Yes (24/10/2016)	5	5	10/04/2017	Recruitment Finished	Yes	Study closed. Recruitment target met
13/LO/1758	136392	A Phase III, Randomized, Placebo Controlled, Parallel Group, Double Blind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)	10	No	Yes (31/10/2016)	10	10	31/10/2016	Recruitment Finished	Yes	Study closed. Recruitment target met
15/SS/0032	165287	An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease (Starbeam Extension)	1	No	Yes (09/02/2017)	4	4	09/02/2017	Recruitment Finished	Yes	Study closed. Recruitment target met